Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Stuart Orkin

During Stuart Orkin’s training as a physician-scientist, he decided to focus on pediatric blood disorders as an area where disease genetics could connect directly to scientific investigations. His work in this field ultimately identified the genetic mutations responsible for thalassemia and chronic granulomatous disease. Recently, his focus has shifted toward singling out hematopoietic targets that can be exploited to treat hematological disorders, including leukemia and sickle cell disease. In this issue of the JCI, Editor at Large Ushma Neill interviews Dr. Orkin to discuss his path toward medicine and scientific research as well as the stories behind these highlights of his research career.  

Published April 3, 2017, by Ushma S. Neill

Conversations with Giants in Medicine

Related articles

A conversation with Stuart Orkin
Ushma S. Neill
Ushma S. Neill
Published April 3, 2017
Citation Information: J Clin Invest. 2017;127(4):1119-1120. https://doi.org/10.1172/JCI93915.
View: Text | PDF
Conversations with Giants in Medicine

A conversation with Stuart Orkin

  • Text
  • PDF
Abstract

Authors

Ushma S. Neill

×
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts